Compare GEF & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GEF | SRRK |
|---|---|---|
| Founded | 1877 | 2012 |
| Country | United States | United States |
| Employees | 15660 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.2B |
| IPO Year | 1994 | 2018 |
| Metric | GEF | SRRK |
|---|---|---|
| Price | $70.71 | $43.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 18 |
| Target Price | ★ $85.60 | $70.44 |
| AVG Volume (30 Days) | 319.4K | ★ 1.6M |
| Earning Date | 11-03-2026 | 11-10-2026 |
| Dividend Yield | ★ 3.48% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,448,100,000.00 | N/A |
| Revenue This Year | $1.08 | N/A |
| Revenue Next Year | $2.12 | $565.83 |
| P/E Ratio | $4.09 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $59.91 | $35.53 |
| 52 Week High | $90.57 | $61.76 |
| Indicator | GEF | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 24.43 | 45.41 |
| Support Level | $69.35 | $38.72 |
| Resistance Level | $70.84 | $51.59 |
| Average True Range (ATR) | 2.74 | 2.44 |
| MACD | -0.96 | 0.24 |
| Stochastic Oscillator | 1.34 | 20.88 |
Greif Inc is a producer of industrial packaging products and services with manufacturing facilities located in many countries. It offers a comprehensive line of rigid industrial packaging products, such as steel, fiber, and plastic drums, rigid intermediate bulk containers, closure systems for industrial packaging products, transit protection products, water bottles and remanufactured and reconditioned industrial containers, and services, such as container life cycle management, blending, filling, logistics, warehousing, and other packaging services. The company operates in three reportable business segments including Global Industrial Packaging, Paper Packaging and Services, and Land Management. It operates in USA, Europe, Middle East, Africa and Asia and Other Americas.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.